Mechanism of Action (MoA) Lipidomics for Target Identification & Validation

Drug mechanism-of-action (MoA) work often stalls when transcript/protein signals don't explain phenotype—or when membrane biology and lipid signaling are the real levers. Our lipidomics workflows help biopharma and biotech teams connect drug perturbations → lipid pathway shifts → actionable target hypotheses, then confirm them with absolute quantification and mechanistic deep dives.

Key capabilities

  • Drug perturbation lipidomics to triage hits and surface pathway-level MoA clues (LC–MS/MS, HRAM)
  • Targeted lipidomics quantification (MRM/PRM) for dose–response, time course, and batch-to-batch reproducibility
  • Spatial / subcellular lipidomics to localize MoA to organelles, membranes, or tissue microenvironments
Request Analysis

Submit Your Request Now

×

Our services have earned the trust of companies, schools, and organizations globally, and we remain dedicated to maintaining that trust.

Boston University
University at Buffalo
UMass Medical School
Hawaii Pacific University
Medizinische Fakultät
Louisiana State University
Nyulangone
Nature's Fynd
Dietary Supplement Manufacturer
  • Trends & Challenges
  • Integrated Solutions
  • Technical Advantages
  • Case Studies
  • FAQ

A Practical Solution Matrix For MoA Programs

Most "Target Identification & MoA Research" programs are iterative—not linear. Teams often loop across:

Bundle A — High-resolution lipidome profiling

Bundle A is designed to establish an unbiased lipidome fingerprint following perturbation, enabling pathway surfacing and hypothesis generation when the MoA is not yet defined.

Discovery: Hit Triage (Unbiased fingerprinting)

Scientific goal

Build a high-resolution lipidome profile after drug perturbation to surface primary pathways and proximal lipid changes.

Recommended Services:
(Untargeted) Lipidomics Profiling Service, Cell Lipidomics Service, Untargeted Lipidomics Bioinformation Analysis
Best-fit scenarios

Early screens, unknown MoA, phenotype-first programs, or limited prior pathway knowledge.

Typical study design notes (practical)
  • Supports comparative designs (treated vs control; multiple conditions), and is commonly used to identify candidate lipid classes/species for downstream targeted confirmation.
  • Suitable when broad coverage is required before narrowing to specific enzymes/transporters/receptors.

Discovery: Biofluid / Translational Bridge (Plasma/Serum)

Scientific goal

Evaluate whether lipid signatures observed in discovery translate to plasma/serum to enable minimally invasive, biomarker-like readouts for downstream studies.

Recommended services
Plasma Lipidomics Analysis Service, (Untargeted) Lipidomics Profiling Service
Best-fit scenarios

When a minimally invasive readout is needed to support later studies.

Typical study design notes (practical)
  • Commonly paired with discovery profiling to assess concordance between tissue/cell signatures and circulating lipid changes.
  • Useful for establishing translational monitoring candidates for subsequent pharmacology studies.

Bundle B — Absolute quantification

Bundle B supports MoA validation by providing quantitative evidence for defined lipid classes and pathways across dose/time/batch, enabling more robust comparisons and decision-making.

Validation: Target Hypothesis (Quantitative confirmation)

Scientific goal

Confirm specific lipid classes associated with candidate targets (e.g., sphingolipid enzymes, phospholipid remodeling) using targeted quantification suitable for dose–response and time-course designs.

Recommended services
Targeted Lipidomics Service, Glycerophospholipids Analysis Service, Sterol Lipids Analysis Service
Best-fit scenarios

When candidate pathways/targets are already prioritized and quantitative evidence is required across dose/time/batch.

Typical study design notes (practical)
  • Often used to convert discovery findings into reproducible, decision-grade datasets (e.g., cross-batch comparability).
  • Appropriate for confirming pathway engagement and supporting compound ranking or optimization decisions.

Validation: Inflammation / Signaling MoA (Lipid mediators)

Scientific goal

Quantify bioactive lipid mediators to connect MoA to downstream signaling outputs (COX/LOX/CYP) and inflammatory pathway involvement.

Recommended services
Oxylipin Quantification and Pathway Profiling, Targeted Lipidomics Service
Best-fit scenarios

When mediator biology is a plausible proximal mechanism or when safety/toxicity signals suggest inflammatory pathway engagement.

Typical study design notes (practical)
  • Frequently applied when the MoA hypothesis involves eicosanoid/oxylipin signaling or inflammation-linked phenotypes.
  • Complements targeted lipid class quantification by adding mechanistic signaling context.

Bundle C — Imaging / localization and pathway flux support

Bundle C is intended for situations where bulk profiling is insufficient—either because spatial heterogeneity matters or because additional evidence is required to distinguish where changes occur and whether a pathway is functionally rewired.

Deep Insight: Where the MoA Happens (Spatial localization)

Scientific goal

Localize lipid changes across tissue regions and evaluate heterogeneity (e.g., responder vs non-responder areas) to resolve effects obscured by bulk averages.

Recommended services
MALDI-Imaging Lipidomic Service, Tissues Lipidomics Service
Best-fit scenarios

When bulk tissue averages hide localized responses (tumor margin, brain regions, immune infiltrates).

Typical study design notes (practical)
  • Supports region-resolved mechanism interpretation in heterogeneous tissues.
  • Useful for linking lipid alterations to histologically or anatomically defined regions.

Deep Insight: Causality / Pathway Flux (Isotope tracing)

Scientific goal

Assess whether a pathway is functionally rewired (synthesis vs turnover) using isotope tracing, providing stronger support than steady-state abundance alone.

Recommended services
Metabolic Flux Analysis Services, Targeted Lipidomics Service
Best-fit scenarios

When stronger causal inference is required to support target validation decisions beyond steady-state lipid abundance.

Typical study design notes (practical)
  • Helps interpret whether observed changes arise from altered biosynthesis, remodeling, or degradation.
  • Commonly used to strengthen mechanism claims prior to major program decisions.

Technical Advantages That Make MoA Lipidomics Actionable

Study Design And Pre-Analytics That Protect Labile Lipids

MoA signals can be distorted by collection/handling variation. We align pre-analytics to your matrix (cells, tissue, plasma/serum) and enforce consistent handling. For planning, use the site's sample size and collection guidance.

Quantification Strategy Built For Dose–Response And Batch Comparability

For validation, LC–MS/MS in MRM/PRM with stable-isotope internal standards supports absolute quantification of selected lipid classes and reproducible comparisons across time courses and batches. Our targeted offering is designed for precise quantification and structural characterization.

Interpretation Layer That Moves From Features To Biology

MoA decisions require interpretable outputs: class-level shifts, pathway grouping, QC visibility, and statistics that scale from discovery to validation. Bioinformatics deliverables include visualizations such as heatmaps and PCA, supporting decision-ready reporting.

Selected Case Studies

Client Publication: Xia, T., Wu, X., Hong, E., et al. (2023). PLOS Pathogens. DOI: 10.1371/journal.ppat.1011232
Client Profile: Research team investigating viral entry mechanisms and host lipid metabolism, where glycosphingolipids modulate membrane fusion.

Targeted Sphingolipid Quantitation for Membrane-Fusion MoA Support

Analytical Challenge

Precisely track structurally similar glycosphingolipids (e.g., GlcCer vs GalCer) and determine whether the pathway signal reflects causal MoA involvement (entry/fusion) rather than downstream stress effects—something that broad “omics” layers often fail to resolve.

Our Solution & Technology

We recommend a Bundle B validation path centered on targeted lipidomics (LC–MS/MS, MRM/PRM) for sphingolipid-class quantitation, with a panel designed around MoA hypotheses (glycosphingolipid biosynthesis / remodeling). This enables clear pathway engagement readouts across inhibitor treatment, genetic perturbation, or time-course designs.

Outcome & Value For Target Identification & MoA Research
  • MoA anchoring: Quantitative sphingolipid readouts provide a direct biochemical anchor for mechanism hypotheses when membrane biology is central.
  • Cleaner target deconvolution: Helps prioritize upstream enzymes/transporters as candidate targets and guides follow-up validation experiments.
  • Formulation relevance (optional extension): The same lipid classes are also relevant to vesicle membranes and lipid-based delivery systems, supporting cross-program learning.
Heat map showing intracellular GalCer and GlcCer levels in 293T cells with and without NB-DNJ treatment.
Heat map of the levels of intracellular GalCer and GlcCer in 293T cells with or without NB-DNJ treatment.
Figure illustrating that downstream glycosphingolipids are not required for infection, supporting GlcCer-centered pathway interpretation.
Glycosphingolipid downstream of GlcCer is not required for HRTV infection.
Client Publication: An, S., Yan, X., Chen, H., Zhou, X. (2023). Molecules. DOI: 10.3390/molecules28196751
Client Profile: Research team running an in vivo pharmacology model and needing an unbiased lipidomics layer to translate phenotype into mechanistic hypotheses and follow-up validation targets.

Untargeted Lipidomics for MoA Hypothesis Generation and Validation Handoff

Analytical Challenge

Early MoA work often starts with uncertainty: which lipid classes matter, which changes are consistent across matrices (serum/urine), and which signals are robust enough to justify a targeted validation panel for lead/target decisions.

Our Solution & Technology

We recommend Bundle A discovery using HRAM LC–MS/MS untargeted lipidomics (e.g., Orbitrap-class data quality expectations), combined with structured multivariate analysis (PCA/OPLS-DA) to prioritize lipid pathways and shortlist candidates for Bundle B targeted quantification (MRM/PRM) in a next step.

Outcome & Value For Target Identification & MoA Research:
  • Fast MoA triage: Converts phenotype complexity into interpretable lipid-pattern signatures (class-level and pathway-level shifts).
  • Validation-ready outputs: Produces a shortlist of lipid candidates suitable for building a targeted panel for dose–response, time course, and reproducibility checks.
  • Mechanism narrative support: Provides visual evidence (PCA/OPLS-DA/heatmap + pathway map) that can be carried into MoA communication and internal decision packages (RUO).
PCA score plots showing group separation based on untargeted lipidomics profiles in serum and urine.
PCA score plot of ESI+  and ESI−  of serum and urine of six components. ((a) serum positive ion pattern, (b) serum negative ion pattern, (c) urine positive ion pattern, (d) urine negative ion pattern.)
Heat map showing relative changes of differential lipid metabolites across experimental groups.
Heat map of the most abundant lipid metabolites in rat serum and urine (showing changes in levels of 52 lipids in response to the normal, PWE, PAE, and PTF treatment groups compared to the AA group).
Pathway map summarizing lipid metabolism pathways implicated by differential lipidomics results.
Map of RA-related lipid metabolism pathways.

Frequently Asked Questions

How does lipidomics differ from metabolomics for drug target identification?
While metabolomics focuses on water-soluble small molecules (sugars, amino acids), lipidomics specifically targets hydrophobic lipid species that regulate membrane structure and signaling. For targets involving GPCRs, ion channels, or ferroptosis, lipidomics provides critical functional insights—such as membrane fluidity changes or lipid mediator signaling—that standard metabolomics misses.
Can you handle small sample sizes from high-throughput screening (HTS)?
Yes. For targeted validation (Bundle B), we have optimized extraction protocols for micro-scale samples, including 96-well plate cell lysates. However, for unbiased discovery (Bundle A), we recommend standard sample amounts (e.g., 1x10^6 cells) to ensure adequate coverage of low-abundance features like signaling lipids.
Do you support multi-omics integration for MoA studies?
Yes. We provide support for integrating lipidomics data with transcriptomics (RNA-seq) or proteomics datasets. By mapping lipid changes (e.g., ceramide accumulation) alongside gene expression shifts (e.g., upregulation of CerS enzymes), we help construct a robust, multi-layered evidence chain for your target hypothesis.
Can you quantify proprietary or novel lipids not in public databases?
Yes. For novel drug-lipid conjugates or proprietary synthetic lipids, we develop custom quantification methods under our validation service. You simply need to provide a small amount of the pure standard. Our team will optimize specific MRM transitions and collision energies on our QTRAP system to build a robust assay for your specific molecule.
How do you differentiate between lipid structural isomers in MoA analysis?
We utilize advanced chromatographic separation (such as SFC or specialized LC columns) combined with high-resolution MS/MS to resolve structural isomers. This allows us to distinguish between biologically distinct species, such as 1,2-DSPC vs. 1,3-DSPC or different fatty acid double-bond positions, which is often critical for accurate pathway mapping and patent support.
What specific signaling panels do you offer for inflammation-related MoA?
We offer comprehensive targeted panels for bioactive lipid mediators, including eicosanoids (prostaglandins, leukotrienes) and specialized pro-resolving mediators (SPMs like resolvins). These panels are essential for elucidating the immunomodulatory mechanism of action for anti-inflammatory or autoimmune therapeutic candidates.
Is it possible to trace lipid metabolic flux to understand drug effects?
Yes. We offer metabolic flux analysis using stable isotope-labeled tracers (e.g., 13C-palmitate or 13C-glucose). This allows you to distinguish between static lipid levels and dynamic rates of synthesis or turnover, revealing whether a drug inhibits a pathway's enzyme activity or merely alters uptake/transport.

References

  1. A human metabolic map of pharmacological perturbations reveals drug modes of action. Nature Biotechnology, 2024. https://doi.org/10.1038/s41587-024-02524-5
  2. Native MS-guided lipidomics to define endogenous lipid microenvironments of eukaryotic receptors and transporters. Nature Protocols, 2024. https://doi.org/10.1038/s41596-024-01037-4
  3. The lipidomics reporting checklist: a framework for transparency of lipidomic experiments and repurposing resource data. Journal of Lipid Research, 2024. https://doi.org/10.1016/j.jlr.2024.100621
  4. Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion. PLOS Pathogens, 2023. https://doi.org/10.1371/journal.ppat.1011232
  5. Investigation of the Mechanism of Action of Periploca forrestii Schltr. Extract on Adjuvant Collagen Rats Based on UPLC-Q-Orbitrap-HRMS Non-Targeted Lipidomics. Molecules, 2023. https://doi.org/10.3390/molecules28196751
  6. Integrated Lipidomics and Network Pharmacology Reveal the AMPK-Mediated Therapeutic Mechanism of 3,3′-Diindolylmethane in Hepatic Lipid Metabolism. Antioxidants, 2025. https://doi.org/10.3390/antiox14091093
* Our services can only be used for research purposes and Not for clinical use.

Applications:


Online Inquiry

CONTACT US

Services

Resource

  • USA
  • Tel:
  • Address:
  • Email:
  • Fax:
  • Germany
  • Address:
Copyright © 2026 Creative Proteomics. All rights reserved.